Detalhe da pesquisa
1.
BID expression determines the apoptotic fate of cancer cells after abrogation of the spindle assembly checkpoint by AURKB or TTK inhibitors.
Mol Cancer
; 22(1): 110, 2023 07 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-37443114
2.
Tumour stroma-derived lipocalin-2 promotes breast cancer metastasis.
J Pathol
; 239(3): 274-85, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27038000
3.
Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival.
EMBO J
; 29(6): 1091-104, 2010 Mar 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-20150892
4.
Constitutive activation of B-Raf in the mouse germ line provides a model for human cardio-facio-cutaneous syndrome.
Proc Natl Acad Sci U S A
; 108(12): 5015-20, 2011 Mar 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-21383153
5.
Phytoremediation Potential of Different Genotypes of Salix alba and S. viminalis.
Plants (Basel)
; 13(5)2024 Mar 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-38475581
6.
Quantitative evaluation of trastuzumab deruxtecan pharmacokinetics and pharmacodynamics in mouse models of varying degrees of HER2 expression.
CPT Pharmacometrics Syst Pharmacol
; 2024 Mar 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-38532525
7.
Identification of NOG as a specific breast cancer bone metastasis-supporting gene.
J Biol Chem
; 287(25): 21346-55, 2012 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22547073
8.
Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer.
Clin Cancer Res
; 29(16): 3237-3249, 2023 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37289191
9.
Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.
NPJ Breast Cancer
; 9(1): 64, 2023 Aug 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37543694
10.
The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance.
Cancer Res
; 83(23): 3989-4004, 2023 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37725704
11.
Differential ABC transporter expression during hematopoiesis contributes to neutrophil-biased toxicity of Aurora kinase inhibitors.
Nat Commun
; 13(1): 6021, 2022 10 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36224199
12.
The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cells.
NPJ Precis Oncol
; 6(1): 95, 2022 Dec 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-36575215
13.
VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status.
J Hematol Oncol
; 14(1): 186, 2021 11 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34742344
14.
Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I.
Mol Cancer Ther
; 19(11): 2298-2307, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32943544
15.
ERK1/2 Signaling Induces Upregulation of ANGPT2 and CXCR4 to Mediate Liver Metastasis in Colon Cancer.
Cancer Res
; 80(21): 4668-4680, 2020 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32816905
16.
Using cells devoid of RAS proteins as tools for drug discovery.
Mol Carcinog
; 48(11): 1038-47, 2009 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-19526460
17.
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.
NPJ Breast Cancer
; 9(1): 69, 2023 Aug 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-37596288
18.
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.
NPJ Breast Cancer
; 9(1): 76, 2023 Sep 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-37726304
19.
MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer.
Nat Cell Biol
; 20(2): 211-221, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29358704
20.
Publisher Correction: MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer.
Nat Cell Biol
; 20(8): 990, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29674681